Advances in nanobiotechnology-propelled multidrug resistance circumvention of cancer

被引:18
|
作者
Chen, Jie [1 ,2 ]
Yu, Xin [3 ]
Liu, Xinyu [3 ]
Ni, Jinliang [1 ]
Yang, Guangcan [1 ]
Zhang, Kun [1 ]
机构
[1] Tongji Univ, Sch Med, Cent Lab, Shanghai Tenth Peoples Hosp, 301 Yan Chang Zhong Rd, Shanghai 200072, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Ultrasound, 241 West Huaihai Rd, Shanghai 200030, Peoples R China
[3] Tongji Univ, Sch Med, Dept Med Oncol, Shanghai Pulm Hosp,Thorac Canc Inst, 507 Zheng Min Rd, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
NEAR-INFRARED LIGHT; IRON-OXIDE NANOPARTICLES; DRUG-DELIVERY SYSTEM; CO-DELIVERY; PHOTODYNAMIC THERAPY; BREAST-CANCER; MAGNETIC HYPERTHERMIA; POLYMERIC NANOPARTICLES; SYNERGISTIC TREATMENT; SILICA NANOPARTICLES;
D O I
10.1039/d2nr04418h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Multidrug resistance (MDR) is one of the main reasons for the failure of tumor chemotherapy and has a negative influence on the therapeutic effect. MDR is primarily attributable to two mechanisms: the activation of efflux pumps for drugs, which can transport intracellular drug molecules from cells, and other mechanisms not related to efflux pumps, e.g., apoptosis prevention, strengthened DNA repair, and strong oxidation resistance. Nanodrug-delivery systems have recently attracted much attention, showing some unparalleled advantages such as drug targeting and reduced drug efflux, drug toxicity and side effects in reversing MDR. Notably, in drug-delivery platforms based on nanotechnology, multiple therapeutic strategies are integrated into one system, which can compensate for the limitations of individual strategies. In this review, the mechanisms of tumor MDR as well as common vectors and nanocarrier-combined therapy strategies to reverse MDR were summarized to promote the understanding of the latest progress in improving the efficiency of chemotherapy and synergistic strategies. In particular, the adoption of nanotechnology has been highlighted and the principles underlying this phenomenon have been elucidated, which may provide guidance for the development of more effective anticancer strategies.
引用
收藏
页码:12984 / 12998
页数:15
相关论文
共 50 条
  • [41] Targeting multidrug resistance in cancer
    Szakács, G
    Paterson, JK
    Ludwig, JA
    Booth-Genthe, C
    Gottesman, MM
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (03) : 219 - 234
  • [42] Multidrug resistance in prostate cancer
    van Brussel, JR
    Mickisch, GHJ
    ONKOLOGIE, 2003, 26 (02): : 175 - 181
  • [43] Autophagy and multidrug resistance in cancer
    YingJie Li
    YuHe Lei
    Nan Yao
    ChenRan Wang
    Nan Hu
    WenCai Ye
    DongMei Zhang
    ZheSheng Chen
    Chinese Journal of Cancer, 2017, 36 (08) : 342 - 351
  • [44] Autophagy and multidrug resistance in cancer
    Li, Ying-Jie
    Lei, Yu-He
    Yao, Nan
    Wang, Chen-Ran
    Hu, Nan
    Ye, Wen-Cai
    Zhang, Dong-Mei
    Chen, Zhe-Sheng
    CHINESE JOURNAL OF CANCER, 2017, 52 : 52
  • [45] Imaging of multidrug resistance in cancer
    Dizdarevic, S.
    Peters, A. M.
    CANCER IMAGING, 2011, 11 (01): : 1 - 8
  • [46] Targeting multidrug resistance in cancer
    Gergely Szakács
    Jill K. Paterson
    Joseph A. Ludwig
    Catherine Booth-Genthe
    Michael M. Gottesman
    Nature Reviews Drug Discovery, 2006, 5 : 219 - 234
  • [47] MULTIDRUG-RESISTANCE IN CANCER
    FERRY, DR
    KERR, DJ
    BRITISH MEDICAL JOURNAL, 1994, 308 (6922): : 148 - 149
  • [48] Proteins in cancer multidrug resistance
    Popeda, Marta
    Pluciennik, Elzbieta
    Bednarek, Andrzej K.
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2014, 68 : 616 - 632
  • [49] Multidrug transporters in cancer resistance
    Revista de Oncología, 2002, 4 (4): : 167 - 169
  • [50] Multidrug resistance in cancer (review)
    Srivastava, RK
    Srivastava, AR
    ChoChung, YS
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (05) : 879 - 884